Kingworld Medicines Group Ltd. (HK:1110)
:1110
Want to see HK:1110 full AI Analyst Report?
1110 Stock Chart & Stats
HK$0.53
>-HK$0.01(-1.12%)
At close: 4:00 PM EST
HK$0.53
>-HK$0.01(-1.12%)
Day’s Range― - ―
52-Week RangeHK$0.41 - HK$0.78
Previous CloseN/A
Volume780.00K
Average Volume (3M)1.11M
Market Cap
HK$251.70M
Enterprise ValueHK$381.70M
Total Cash (Recent Filing)HK$274.70M
Total Debt (Recent Filing)HK$434.05M
Price to Earnings (P/E)4.2
Beta0.22
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.87%
Share Statistics
EPS (TTM)0.02
Shares Outstanding622,499,940
10 Day Avg. Volume874,800
30 Day Avg. Volume1,111,766
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)0.44
Price to Sales (P/S)0.30
P/FCF Ratio4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Defensive Distribution Business ModelKingworld's core business is distribution and sales of pharmaceuticals and health products to wholesalers, pharmacies and hospitals. A distribution model tied to end-market healthcare demand is relatively defensive and provides stable revenue channels and cash flow potential over the medium term.
Relatively Stable Gross MarginsReported gross margins in the mid-to-high 20% range indicate the company retains healthy core product economics. Stable gross margins suggest procurement/pricing and product mix remain resilient, giving management scope to address operating cost pressures without impairing core unit profitability over months.
Supportive Equity Cushion On Balance SheetAlthough leverage has risen, a fairly stable equity base and steady asset base provide a cushion against shocks and improve access to credit. This structural balance-sheet support enhances financial flexibility to fund working capital or strategic initiatives over the medium term.
Bears Say
Declining Revenue TrendSales have shifted from prior growth into decline across 2024–2025, with reported revenue contraction and negative multi-year growth. Persistent top-line weakness erodes scale, limits bargaining power with suppliers, and makes margin recovery and reinvestment harder without structural market share or product fixes.
Profitability Compression And Weak ReturnsNet margin and ROE have fallen sharply, signalling weak earnings power despite stable gross margins. Low profitability reduces internal reinvestment capacity, constrains dividend and capex funding, and increases reliance on external financing, which hurts long-run competitiveness and strategic optionality.
Rising Leverage And Inconsistent Cash GenerationLeverage has increased materially while free cash flow has been inconsistent and declined year-over-year. Higher debt plus volatile cash generation raises refinancing and liquidity risk, reducing resilience to demand shocks and limiting ability to execute medium-term investments or stabilize margins.
Kingworld Medicines Group Ltd. News
1110 FAQ
What was Kingworld Medicines Group Ltd.’s price range in the past 12 months?
Kingworld Medicines Group Ltd. lowest stock price was HK$0.41 and its highest was HK$0.78 in the past 12 months.
What is Kingworld Medicines Group Ltd.’s market cap?
Kingworld Medicines Group Ltd.’s market cap is HK$251.70M.
When is Kingworld Medicines Group Ltd.’s upcoming earnings report date?
Kingworld Medicines Group Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 98 days.
How were Kingworld Medicines Group Ltd.’s earnings last quarter?
Kingworld Medicines Group Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.031 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.031.
Is Kingworld Medicines Group Ltd. overvalued?
According to Wall Street analysts Kingworld Medicines Group Ltd.’s price is currently Overvalued.
Does Kingworld Medicines Group Ltd. pay dividends?
Kingworld Medicines Group Ltd. pays a Annually dividend of HK$0.032 which represents an annual dividend yield of 5.87%. See more information on Kingworld Medicines Group Ltd. dividends here
What is Kingworld Medicines Group Ltd.’s EPS estimate?
Kingworld Medicines Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kingworld Medicines Group Ltd. have?
Kingworld Medicines Group Ltd. has 622,499,940 shares outstanding.
What happened to Kingworld Medicines Group Ltd.’s price movement after its last earnings report?
Kingworld Medicines Group Ltd. reported an EPS of HK$0.031 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Kingworld Medicines Group Ltd.?
Currently, no hedge funds are holding shares in HK:1110
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kingworld Medicines Group Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.19%
12-Months-Change
Fundamentals
Return on Equity
1.78%
Trailing 12-Months
Asset Growth
6.64%
Trailing 12-Months
Company Description
Kingworld Medicines Group Ltd.
Kingworld Medicines Group Limited, an investment holding company, distributes branded imported pharmaceutical and healthcare products. The company also supplies pharmaceutical, healthcare, general foodstuffs, and medical products. It offers products for various functional categories, such as cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and Mentholatum Product Range brands. The company also manufactures and sells electrotherapeutic and physiotherapeutic devices, and general medical examination devices. It serves in the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and internationally. The company was founded in 1996 and is headquartered in Shenzhen, the People's Republic of China.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―